Imagion Business Update
Released
Released
Announcement PDF
Company Announcement
IMAGION BIOSYSTEMS LIMITED
ASX: IBX
28 February 2024
Imagion Business Update
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through
the early detec on of cancer, reports staff and cost reduc ons including transi on plans for the
departure of its Chief Financial Officer.
The Company’s CFO, Mr Geoff Hollis, has tendered his resigna on with a planned departure effec ve
May 10th. Mr Hollis has served as the Company’s Chief Financial Officer and Company Secretary since
December 2020 and will remain engaged with the Company as Company Secretary. “Geoff has been a
valuable and highly respected contributor,” remarked Execu ve Chairman, Bob Proulx. “We wish him
well in his new endeavors.”
Addi onally, the Company has lowered opera ng expenses through further staff reduc ons and has
taken steps to reduce other opera ng costs going forward. With the comple on of the Company’s
MagSense® HER2 Phase I study any ac vity related to the IND filing for Phase II has been put on-hold
pending further financing. However, essen al personnel and infrastructure necessary to realize
revenue from nanopar cle sales remains in-tact.
“Although the Company achieved record revenues through the sale of nanopar cles to 3rd par es last
year, such revenues are not yet sufficient to fund the Company’s overall programs”, said Bob Proulx,
Execu ve Chairman. “As a result we have taken steps to further reduce opera ng expenses to align
with our projected income while we con nue to explore financing op ons and strategic partnerships
that could allow us to realize the value of our technology.”
ENDS
About Imagion Biosystems
Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASXlisted company dedicated to developing innova ve medical imaging technologies for various cancer
types. Imagion Biosystems is advancing clinical development of its MagSense® pla orm technology to
revolu onize cancer diagnosis, introducing molecular imaging to MRI. The Company’s lead program
has demonstrated its innova ve technology embodied in MagSense® HER2 Imaging Agent (MSH2IA)
is safe and well-tolerated in pa ents diagnosed with HER2+ breast cancer. Imagion Biosystems’
MagSense® pipeline includes prostate cancer, ovarian cancer, pancrea c cancer, and brain cancer
programs.
For more informa on, visit h ps://imagionbiosystems.com/investor-hub/
AuthorisaƟon & AddiƟonal informaƟon
This announcement was authorised by the Disclosure Commi ee of Imagion Biosystems Limited.
Media & Investor RelaƟons:
Geoff Hollis, CFO and Company Secretary
geoff.hollis@imagionbio.com
Share your feedback
Discover